Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press
Series of Journals
Center for Evidence-Based and Translational Medicine of Wuhan University
The title
The title
The keywords
The author
Submit
Home
About us
Journal Introduction
Chief Editor
Editorial Committee
Author Center
Submission Guide
Assignment Agreement
ConflictofInterest
Articles
Subscribe
Copyright
Contact us
Draft submission system
Author login
Author register
Reviewer login
Editor login
Home
Articles
Vol 34,2025 No.11
The title
The title
The keywords
The author
New Online
Vol 34,2025
Vol 33,2024
Vol 32,2023
No.11
No.10
No.9
No.8
No.7
No.6
No.5
No.4
No.3
No.2
No.1
Contents
Vol 34,2025 No.11
Date of publication: November 15, 2025
Get cover
Get contents
Prev
Vol 34,2025 No.10
Guide on Methodological Standards in Pharmacoepidemiology (2nd edition) and their series interpretation (11): introduction and examples of pharmacovigilance impact research
NIE Xiaolu
SONG Haibo
REN Jingtian
YAN Jinan
WU Jiarui
ZHAN Siyan
SUN Feng
2025,34(11):1233-1243
Pharmacoepidemiology
Methodology
Guidelines
Pharmacovigilance impact research
Details
Download
Mobile
Influencing factors for the duration of prophylactic antibacterial therapy in patients with total hip arthroplasty
FAN Xinxing
XIONG Jian
LI Lunjin
LIU Xiao
YANG Zhiyong
SHI Zheng
2025,34(11):1244-1251
Total hip arthroplasty
Antibiotics
Prophylaxis
Course of treatment
Influencing factors
Details
Download
Mobile
Analysis of the occurrence and related factors of drug-induced liver injury in postoperative analgesia with propacetamol
JIN Lei
SHEN Yanlin
LI Min
WANG Fang
LI Ping
Ge Youting
YAO Huijuan
2025,34(11):1252-1257
Propacetamol
Drug-induced liver injury
Adverse drug reactions
Risk factors
Details
Download
Mobile
Clinical study on the combination of wentong guasha with herbal enema in improving acute attack of chronic pelvic inflammatory disease
LIU Li
FENG Jinping
OU Yuyi
OU Huizhi
ZHANG Ying
HE Siyuan
LIU Shuai
LYU Jun
2025,34(11):1258-1264
Chronic pelvic inflammatory disease
Acute attack
Wentong guasha
Herbal enema
Details
Download
Mobile
Insights on facilitators and barriers to regulating non-medical use of prescription opioids: a qualitative study
DUAN Yuehan
ZHOU Huziwei
YANG Yingzi
WEN Qiaorui
CHU Hongling
WANG Jingling
JIANG Zhiqin
SUN Yexiang
ZHU Yu
WANG Shengfeng
2025,34(11):1265-1275
Opioid
Non-medical use
Drug abuse
Substance addiction
Drug regulation
Qualitative study
Details
Download
Mobile
Analysis of the correlation between medication regimen complexity and glycemic control among type 2 diabetes mellitus in the elderly
ZHI Junna
QU Guohong
WU Ling
TAN Zhen
2025,34(11):1276-1282
Medication regimen complexity
Elderly
Type 2 diabetes mellitus
Glycemic control
Details
Download
Mobile
Analysis on the burden and trend of musculoskeletal diseases in China based on GBD 2021
ZHAO Duowei
WEI Jiantong
JIANG Jin
XU Shenggang
ZHANG Hui
2025,34(11):1283-1293
Musculoskeletal diseases
Gout
Osteoarthritis
Rheumatoid arthritis
Low back pain
Neck pain
Burden of disease
Changing trend
Details
Download
Mobile
Efficacy and safety of tegoprazan in the treatment of gastroesophageal reflux disease: a systematic review and Meta-analysis
LU Ronghua
LIU Jiaojiao
PANG Tengfei
CAI Rui
YUAN Jian
2025,34(11):1294-1301
Tegoprazan
Gastroesophageal reflux disease
Meta-analysis
Systematic review
Randomized controlled trial
Details
Download
Mobile
Toripalimab for the treatment of advanced esophageal cancer: a rapid health technology assessment
YANG Shou
NIE Ying
GONG Yuan
KANG Shuo
HOU Yibing
WANG Xiaohui
PAN Zhenhua
2025,34(11):1302-1310
Toripalimab
Advanced esophageal cancer
Rapid health technology assessment
Effectiveness
Safety
Economy
Details
Download
Mobile
Rapid health technology assessment of avatrombopag for the treatment of primary immune thrombocytopenia in adults
LI Zhou
LING Ya
ZHANG Jie
ZHU Ling
2025,34(11):1311-1319
Avatrombopag
Primary immune thrombocytopenia
Efficacy
Safety
Economy
Rapid health technology assessment
Details
Download
Mobile
Research advances in adverse drug reactions and their management in targeted therapy for driver gene-positive advanced non-small cell lung cancer
FAN Jiameng
PAN Lei
2025,34(11):1320-1329
Non-small cell lung cancer
Target therapy
Adverse drug reactions
Symptom management
Biomarker
Details
Download
Mobile
Pharmaceutical care for a case of abemaciclib-induced interstitial lung disease
DING Liping
WU Wei
WANG Chunhui
2025,34(11):1330-1334
Abemaciclib
Interstitial lung disease
Breast cancer
Pharmaceutical care
Details
Download
Mobile
Pharmaceutical practice of bevacizumab-induced refractory hypertension and proteinuria in a patient with advanced lung adenocarcinoma
YAN Jiaju
YUAN Yongyong
LIU Meng
2025,34(11):1335-1339
Bevacizumab
Lung adenocarcinoma
Resistant hypertension
Proteinuria
Phamaceutical care
Details
Download
Mobile
Anti-infection treatment and pharmaceutical care for a patient with liver cirrhosis complicated with severe psittacosis
XING Baiqian
LIU Hunan
SUN Yihong
LU Nianfang
LI Zhongdong
2025,34(11):1340-1346
Liver cirrhosis
Chlamydia psittaci
Omadacycline
Voriconazole
Posaconazole
Pharmaceutical care
Details
Download
Mobile
Acute drug-induced liver injury associated with tolvaptan in a patient with cardiac amyloidosis: a case report
YAO Tingyi
ZHANG Weixia
2025,34(11):1347-1352
Tolvaptan
Drug-induced liver injury
AL cardiac amyloidosis
Heart failure
Details
Download
Mobile